Paeds · haematology-oncology-and-transfusion
Blood-component therapy in children
Also known as Paediatric transfusion · Red cell transfusion in children · Platelet transfusion in children · Fresh frozen plasma in children · Cryoprecipitate in children · Massive transfusion in children · Patient blood management in children
Fellowship guide to blood-component therapy in children, the deliberate, dose-based use of red cells, platelets, fresh frozen plasma and cryoprecipitate to correct deficits the body cannot correct itself. Covers the separation of one whole-blood donation into four targeted components, the restrictive transfusion philosophy of patient blood management, and the per-kilogram doses that define paediatric practice: neonatal red-cell top-ups typically 15 mL per kg, platelets at 10 to 20 mL per kg, fresh frozen plasma at 15 to 20 mL per kg for multiple clotting-factor deficiency, and cryoprecipitate at 5 to 10 mL per kg for a low fibrinogen. Reviews the transfusion thresholds, from the restrictive haemoglobin of 70 g per litre in the stable critically ill child of the TRIPICU and Cochrane trials to the neonatal platelet threshold of 25 times ten to the nine per litre of the PlaNeT-2 MATISSE trial, the special products of leucodepletion, irradiation and cytomegalovirus-negative blood, the prevention and recognition of transfusion reactions including circulatory overload and acute lung injury, and the massive-transfusion protocol.
Checked against its sources on 5 Sept 2026
On this page
Study tools
Your progress
Saved on this device.
Practise this topic
Target exams
Red flags
- A child transfused too quickly or with too large a volume is at risk of transfusion-associated circulatory overload, a leading cause of transfusion-related death, presenting as respiratory distress and pulmonary oedema during or up to 12 hours after transfusion
- Fever, hypotension and flank pain during the first minutes of a transfusion suggest an acute haemolytic reaction from ABO incompatibility, a never-event that demands stopping the transfusion at once and resampling the patient
- An immunocompromised child given non-irradiated cellular components is at risk of transfusion-associated graft-versus-host disease, which is nearly always fatal and prevented only by irradiating the unit
- A neonate transfused platelets at a high threshold of 50 times ten to the nine per litre bled more, not less, than those at a threshold of 25 in the PlaNeT-2 MATISSE trial, so the lower threshold is preferred
- A child on a thalassaemia or sickle cell transfusion programme needs extended-phenotype-matched red cells to prevent alloimmunisation, which can make future cross-matching impossible
Life stages
Care settings
Clinical exam formats
Board mappings
- Names the four blood components prepared from a whole-blood donation and states the typical neonatal red-cell top-up of 15 mL per kg
- States the restrictive haemoglobin threshold of 70 g per litre for the stable critically ill child and the prophylactic platelet threshold of 10 times ten to the nine per litre
- Lists the bedside checks and observations required before and during a transfusion, and the danger signs that demand stopping it
- Explains patient blood management, restrictive transfusion and the special products of leucodepletion, irradiation and cytomegalovirus-negative blood, and selects the correct product for each clinical scenario
- Coordinates a massive-transfusion protocol in a bleeding child with per-kilogram dosing of red cells, plasma and platelets
- Appraises the TRIPICU, TOP and PlaNeT-2 MATISSE trials and the Cochrane and AABB evidence that set the thresholds
- Neonatal red-cell top-up typically 15 mL per kg, platelets 10 to 20 mL per kg, fresh frozen plasma 15 to 20 mL per kg, cryoprecipitate 5 to 10 mL per kg
- Restrictive haemoglobin threshold of 70 g per litre in the stable critically ill child, 90 to 100 g per litre pre-transfusion in thalassaemia
- Prophylactic platelet threshold 10 times ten to the nine per litre; neonatal platelet threshold 25 rather than 50
- Counsels a family on the reasons, the benefits and the risks of transfusion, and the alternatives of iron and patient blood management
- Builds a transfusion plan for a chronically transfused child that includes phenotype matching, iron surveillance and the avoidance of alloimmunisation
- Synthesises a child with a major haemorrhage into a massive-transfusion protocol with correct per-kilogram ratios
- Level 1: Recognises the indication for each component and the per-kilogram dose, and completes the bedside safety checks
- Level 2: Applies restrictive thresholds, selects special products and recognises transfusion reactions early
- Level 3: Leads a massive-transfusion protocol, coordinates chronic transfusion programmes and drives patient blood management
- The fractionation of whole blood into red cells, platelets, fresh frozen plasma and cryoprecipitate, and the per-kilogram doses
- The restrictive transfusion thresholds of TRIPICU, the Cochrane review, the TOP and PlaNeT-2 MATISSE trials
- The special products and the transfusion reactions, with their prevention and first-line treatment
- Communication of the indication, the risk and the alternatives of transfusion to a family, including the Jehovah Witness context
- Structured assessment of a child before, during and after transfusion for fever, overload and bleeding
- Recognition and immediate management of an acute transfusion reaction
- The four blood components, their per-kilogram doses, and the restrictive transfusion thresholds
- Special products for neonatal, immunocompromised and chronically transfused children
- Prevention and recognition of transfusion reactions, and the massive-transfusion protocol
- Recognition of the indication for transfusion and the correct component and dose
- Application of restrictive thresholds and patient blood management, and selection of special products
- Coordination of a massive-transfusion protocol and the chronic transfusion programme
- Canadian Blood Services approach to component preparation, leucodepletion and CMV-negative provision
- Restrictive thresholds and the per-kilogram doses across the age range
- Chronic transfusion programmes, patient blood management and the management of transfusion reactions
Overview & Definition
Blood-component therapy in children is the deliberate, dose-based use of the parts of donated blood to correct a deficit the child's own marrow or liver cannot correct quickly enough. One whole-blood donation is no longer transfused as a unit. Instead it is separated by centrifugation into four targeted components, each one prepared and stored to do a single job: red cells to carry oxygen, platelets to plug bleeding, fresh frozen plasma to supply clotting factors, and cryoprecipitate to deliver fibrinogen. The paediatric clinician transfuses component child lacks, at a weight-based dose, only when the benefit outweighs the risk. [2]
The philosophy that governs modern transfusion is patient blood management, and its core principle is restraint. A transfusion is a liquid transplant of living tissue from one person to another, and it carries real risks of immunological reaction, circulatory overload, infection and iron overload, so the default is not to transfuse but to treat the cause, to correct iron and vitamin deficiency, to minimise iatrogenic blood loss and to use alternatives such as tranexamic acid. When transfusion is needed, the child receives the smallest effective dose of the correct component, weighed to the kilogram, and observed for the reactions that can follow. The thresholds that trigger a transfusion have fallen steadily over three decades as the trials have shown that less is usually as good and sometimes better. [7][2]
Three ideas make this topic central to the fellowship exam. The first is the per-kilogram dose, because the paediatric transfusion is a weight-based prescription and the candidate who cannot state that neonatal red-cell top-ups typically 15 mL per kg, platelets at 10 to 20 mL per kg, plasma at 15 to 20 mL per kg and cryoprecipitate at 5 to 10 mL per kg cannot prescribe safely. The second is the threshold, because the restrictive haemoglobin of 70 g per litre in the stable critically ill child and the prophylactic platelet count of 10 times ten to the nine per litre are the evidence-based triggers most often examined. The third is safety, because the recognition and prevention of transfusion reactions, and the selection of special products for the neonate and the immunocompromised child, are the bedside skills that mark the safe paediatrician. [1][2]
References11ShowHide
- [1]Lacroix J, Hébert PC, Hutchison JS, et al. Transfusion strategies for patients in pediatric intensive care units. N Engl J Med, 2007.PMID 17442904
- [2]New HV, Berryman J, Bolton-Maggs PH Guidelines on transfusion for fetuses, neonates and older children. Br J Haematol, 2016.PMID 27861734
- [3]Neunert C, Terrell DR, Arnold DM American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv, 2019.PMID 31794604
- [4]Diab YA, Wong EC, Luban NL Massive transfusion in children and neonates. Br J Haematol, 2013.PMID 23432321
- [5]Fustolo-Gunnink SF, Fijnvandraat K, van Klaveren D Preterm neonates benefit from low prophylactic platelet transfusion threshold despite varying risk of bleeding or death. Blood, 2019.PMID 31697817
- [6]Moore CM, D'Amore A, Fustolo-Gunnink S Two-year outcomes following a randomised platelet transfusion trial in preterm infants. Arch Dis Child Fetal Neonatal Ed, 2023.PMID 36810309
- [7]Carson JL, Stanworth SJ, Dennis JA Transfusion thresholds and other strategies for guiding red blood cell transfusion. Cochrane Database Syst Rev, 2025.PMID 41114449
- [8]Kirpalani H, Bell EF, Hintz SR Higher or Lower Hemoglobin Transfusion Thresholds for Preterm Infants. N Engl J Med, 2020.PMID 33382931
- [9]Curley A, Stanworth SJ, Willoughby K Randomized Trial of Platelet-Transfusion Thresholds in Neonates. N Engl J Med, 2019.PMID 30387697
- [10]Kaufman RM, Djulbegovic B, Gernsheimer T Platelet transfusion: a clinical practice guideline from the AABB. Ann Intern Med, 2015.PMID 25383671
- [11]Cazzola M, De Stefano P, Ponchio L, et al. Relationship between transfusion regimen and suppression of erythropoiesis in beta-thalassaemia major. Br J Haematol, 1995.PMID 7734344